Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells
US8900567B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2007 |
| Grant date | Dec 2, 2014 |
| Priority date | — |
| Expiry date | Oct 21, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/124
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of preserving cone cells in the eye of a mammal suffering from a retinal degenerative disease comprises isolating from the bone marrow of the mammal a lineage negative hematopoietic stem cell population that includes endothelial progenitor cells, transfecting cells from the stem cell population with a gene that operably encodes an antiangiogenic fragment of human tryptophanyl tRNA synthetase (TrpRS), and subsequently intravitreally injecting the transfected cells into the eye of the mammal in an amount sufficient to inhibit the degeneration of cone cells in the retina of the eye. The treatment may be enhanced by stimulating proliferation of activated astrocytes in the retina using a laser.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.